Novo Nordisk sees oral pills capturing over third of GLP-1 market by 2030

Core Insights - Oral weight-loss drugs are projected to constitute a third or more of the overall GLP-1 market by 2030, exceeding previous expectations from the company [1] Company Perspective - A Novo Nordisk executive highlighted the increased market share for oral weight-loss drugs, indicating a significant shift in market dynamics [1]